{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:54:38Z","timestamp":1790891678255,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ucl.2026.06.008","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:52:39Z","timestamp":1785455559000},"page":"613-624","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trimodal Therapy for Muscle Invasive Bladder Cancer"],"prefix":"10.1016","volume":"53","author":[{"given":"Michael G.","family":"Dubic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Riggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10364","key":"10.1016\/j.ucl.2026.06.008_bib1","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/S0140-6736(22)01188-6","article-title":"Current best practice for bladder cancer: a narrative review of diagnostics and treatments","volume":"400","author":"Comp\u00e9rat","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.008_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JU.0000000000003981","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; amended 2020, 2024)","volume":"212","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"issue":"19","key":"10.1016\/j.ucl.2026.06.008_bib3","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: a review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"issue":"5_suppl","key":"10.1016\/j.ucl.2026.06.008_bib4","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1200\/JCO.2025.43.5_suppl.698","article-title":"Clinical characteristics and treatment patterns of patients with muscle invasive bladder cancer: a real-world cohort study","volume":"43","author":"Gore","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ucl.2026.06.008_bib5","author":"Zlotta"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.008_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2025.03.017","article-title":"Bladder preservation strategies in muscle-invasive bladder cancer: recommendations from the international bladder cancer group","volume":"89","author":"Gupta","year":"2026","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ucl.2026.06.008_bib8","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ucl.2015.02.002","article-title":"Trimodality therapy in bladder cancer: who, what and when?","volume":"42","author":"Premo","year":"2015","journal-title":"Urol Clin North Am"},{"issue":"6","key":"10.1016\/j.ucl.2026.06.008_bib9","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts general hospital experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur Urol"},{"issue":"20","key":"10.1016\/j.ucl.2026.06.008_bib10","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1200\/JCO.2016.69.2327","article-title":"Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic","volume":"35","author":"Kulkarni","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2026.06.008_bib11","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bju.16366","article-title":"Trimodal therapy vs radical cystectomy in patients with muscle-invasive bladder cancer: a systematic review and meta-analysis of comparative studies","volume":"134","author":"Ditonno","year":"2024","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.008_bib12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/cncr.23137","article-title":"Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience","volume":"112","author":"Perdon\u00e0","year":"2008","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.ucl.2026.06.008_bib13","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2002.11.027","article-title":"Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results","volume":"20","author":"R\u00f6del","year":"2002","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2026.06.008_bib14","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2011.11.010","article-title":"Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience","volume":"61","author":"Efstathiou","year":"2012","journal-title":"Eur Urol"},{"issue":"34","key":"10.1016\/j.ucl.2026.06.008_bib15","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","article-title":"Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of radiation therapy oncology group protocols 8802, 8903, 9506, 9706, 9906, and 0233","volume":"32","author":"Mak","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.008_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102229","article-title":"Patterns of failure after definitive trimodality therapy for muscle-invasive bladder cancer","volume":"23","author":"Kotha","year":"2025","journal-title":"Clin Genitourin Cancer"},{"issue":"27","key":"10.1016\/j.ucl.2026.06.008_bib17","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1200\/JCO.23.00725","article-title":"Bladder-sparing treatment with radical dose radiotherapy is an effective alternative to radical cystectomy in patients with clinically node-positive nonmetastatic bladder cancer","volume":"41","author":"Swinton","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2026.06.008_bib18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eururo.2022.04.017","article-title":"Chemoradiotherapy in muscle-invasive bladder cancer: 10-yr follow-up of the phase 3 randomised controlled BC2001 trial","volume":"82","author":"Hall","year":"2022","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.ucl.2026.06.008_bib19","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(13)70255-9","volume":"14","author":"Mitin","year":"2013","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ucl.2026.06.008_bib20","first-page":"1201","article-title":"The efficacy of trimodal chemoradiotherapy with gemcitabine and cisplatin as a bladder-preserving strategy for the treatment of muscle-invasive bladder cancer: a single-arm phase II study","volume":"52","author":"Kobayashi","year":"2022","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.008_bib21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijrobp.2024.08.007","article-title":"Long-term results of bladder preservation with twice-daily radiation plus 5-flourouracil\/cisplatin or daily radiation plus gemcitabine for MIBC \u2013 updated report of nrg\/rtog 0712: a randomized phase 2 trial","volume":"121","author":"Coen","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.ucl.2026.06.008_bib22","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.1998.16.11.3576","article-title":"Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of radiation therapy oncology group 89-03","volume":"16","author":"Shipley","year":"1998","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2026.06.008_bib23","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.clgc.2021.03.007","article-title":"Trimodality therapy with or without neoadjuvant chemotherapy for muscle invasive bladder cancer","volume":"19","author":"Royce","year":"2021","journal-title":"Clin Genitourin Cancer"},{"issue":"19","key":"10.1016\/j.ucl.2026.06.008_bib25","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ucl.2026.06.008_bib26","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1158\/1078-0432.CCR-24-2636","article-title":"Bladder preservation with durvalumab plus tremelimumab and concurrent radiotherapy in patients with localized muscle-invasive bladder cancer (IMMUNOPRESERVE): a phase II Spanish oncology genitourinary group trial","volume":"31","author":"Garcia-Del-Muro","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ucl.2026.06.008_bib27","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ijrobp.2023.05.013","article-title":"Efficacy and safety of bladder preservation therapy in combination with atezolizumab and radiation therapy (BPT-ART) for invasive bladder cancer: interim analysis from a multicenter, open-label, prospective phase 2 trial","volume":"117","author":"Kimura","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"10.1016\/j.ucl.2026.06.008_bib29","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N Engl J Med"},{"issue":"33","key":"10.1016\/j.ucl.2026.06.008_bib30","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2010.28.4950","article-title":"Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma","volume":"28","author":"Hoskin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.008_bib31","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.euo.2023.05.013","article-title":"Long-term outcomes of chemoradiation for muscle-invasive bladder cancer in noncystectomy candidates. Final results of NRG oncology RTOG 0524\u2014A phase 1\/2 trial of paclitaxel + trastuzumab with daily radiation or paclitaxel alone with daily irradiation","volume":"7","author":"Dahl","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.008_bib32","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.18.00537","article-title":"Bladder preservation with Twice-a-Day radiation plus fluorouracil\/cisplatin or once daily radiation plus gemcitabine for muscle-invasive bladder cancer: NRG\/RTOG 0712\u2014A randomized phase II trial","volume":"37","author":"Coen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2026.06.008_bib33","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1470-2045(20)30607-0","article-title":"Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials","volume":"22","author":"Choudhury","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2026.06.008_bib34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijrobp.2013.06.2044","article-title":"Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK\/01\/004)","volume":"87","author":"Huddart","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ucl.2026.06.008_bib36","article-title":"A prospective study of a resorbable intravesical fiducial marker for bladder cancer radiation therapy","volume":"7","author":"Greer","year":"2021","journal-title":"Adv Radiat Oncol"},{"issue":"24","key":"10.1016\/j.ucl.2026.06.008_bib37","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ucl.2026.06.008_bib38","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1158\/1078-0432.CCR-25-3712","article-title":"ctDNA dynamics and recurrence patterns after organ-sparing trimodality therapy for bladder cancer","volume":"32","author":"Epstein","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ucl.2026.06.008_bib39","doi-asserted-by":"crossref","first-page":"e683","DOI":"10.1016\/S1470-2045(18)30693-4","article-title":"Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer","volume":"19","author":"Miyamoto","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2026.06.008_bib40","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ijrobp.2016.08.023","article-title":"Quality of life in long-term survivors of muscle-invasive bladder cancer","volume":"96","author":"Mak","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.ucl.2026.06.008_bib41","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.17056","article-title":"Cost-effectiveness of trimodal therapy and radical cystectomy for muscle-invasive bladder cancer","volume":"8","author":"Joyce","year":"2025","journal-title":"JAMA Netw Open"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:59:11Z","timestamp":1790888351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014326000613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0094014326000613"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2026.06.008","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trimodal Therapy for Muscle Invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2026.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}